Danaher China Diagnostics Platform Signs Strategic Agreement with Shenzhen National Clinical Research Center for Infectious Diseases

SHANGHAI, March 31, 2021 /PRNewswire/ -- On March 30, 2021, Danaher China Diagnostics Platform signed a strategic agreement with the Shenzhen National Clinical Research Center for Infectious Diseases to launch comprehensive collaboration in multiple fields, including tuberculosis, advance clinical research projects, and strengthen the research, translation, and clinical application of innovative technologies.

Danaher China Diagnostics Platform Signs Strategic Agreement with Shenzhen National Clinical Research Center for Infectious Diseases

Peng Yang, President of Danaher Corporation’s Greater China Region and President of its Diagnostics Platform in China, stated that he was pleased to reach a cooperation intent within just a few months, reflecting the strong alignment between both parties in terms of strategic direction and research capabilities. Today’s strategic signing marks only the beginning of the collaboration, with expectations for more substantial cooperation in the future to jointly lead the development and progress of China’s healthcare industry.

Liu Lei, Director of the Shenzhen National Clinical Research Center for Infectious Diseases and Party Secretary and President of Shenzhen Third People’s Hospital, expressed his hope to establish a normalized communication mechanism, continuously strengthen the translation of scientific research achievements into clinical applications, uphold the concepts of pioneering innovation and the spirit of scientific exploration, and jointly address challenges in clinical medicine.